iGeneTRAiN signs an agreement with Ovation to perform extensive analyses of genomic datasets for discovery of genetic underpinnings of rejection and other complications of transplantation.
May 24, 2017
NEW YORK (GenomeWeb) – Scientific data management firm Ovation Life Sciences announced today that it has received $1.5 million in funding from a group of new and existing investors.
Participants in the financing included StageDotO and Longfellow Ventures.
Ovation’s main products are a lab service for the tracking of samples, workflows, and processes, and a research service for facilitating collaboration and data sharing between separate teams. The company intends to use the money to continue development of its next-generation data layer-as-a-service platforms.
The company also announced today that it has signed an agreement under which its research service will be used by members of the International Genetics and Translational Research in Transplantation Network (iGeneTrain). Specific terms of the deal were not disclosed.
“The premise behind iGeneTrain is that better sharing and understanding of the global data on transplants and their genetic factors will improve outcomes,” Brendan Keating, iGeneTrain Cofounder and University of Pennsylvania researcher, said in a statement. “Our collaboration with Ovation will significantly improve and accelerate that process.”